•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student
other

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences

SC lambasts pharma deptt | CLAT letters patent: NLUJ out HNLU in | SC condemns gov’t officials’ petty appeals | Novartis cancer-drug patent: Final SC round

ASG Siddharth Luthra produces a letter on behalf of the ministry of chemicals in Supreme Court, and invites the wrath of justices Singhvi and Mukhopadhyay. The bench rebuked the department of pharmaceuticals for its slow action in preparing a national list of essential medicines.Was it a silent meeting? The letter states nothing about the deliberations by the GoM [group of ministers] or the status of the proposed policy. Did they actually deliberate or the honourable ministers were meditating during the meeting? You don’t talk when you meditate, right?,” the bench said [Deccan Herald]

Delhi high court impleads CLAT convenor for 2013 HNLU Raipur in the Letters Patent Appeal for the creation of a permanent CLAT body being heard in the court. This year’s CLAT convenor NLU Jodhpur did not file its response in the appeal, despite notice, since it had already wrapped up the admission process for the year. The next hearing is on 15 October [Bar & Bench]

“Disturbed” by the practice of gov’t officials dragging small time claimants up to the Supreme Court in petty cases, the Supreme Court says: “Unless, serious questions of law of general importance arise for consideration or a question which affects large number of persons or the stakes are very high, the courts’ jurisdiction cannot be invoked for resolution of small and trivial matters.” The court was lamenting the lack of gov’t attempts to resolve “earnest disputes” at their end and overburdening the court with appeals [BS]

Final hearings for protection of patent to major Cancer-curing drug Glivec begin in the Supreme Court after the drug-maker Novartis earlier lost a round on the ground that Glivec was not a new molecule but an amended version of an old compound. “We are giving something new to the patients,” said senior advocate Gopal Subramanium acting for Novartis. Generic drug-makers supply medicines to 1.2 billion Indians and poor countries across the world [Reuters]

No comments yet: share your views